Immunotherapeutic strategies for relapse control in acute myeloid leukemia

Blood Reviews

Volumn 27, Issue 5, 2013, Pages 209-216

  Martner, Anna ^a   Thorén, Fredrik Bergh ^a   Aurelius, Johan ^a   Hellstrand, Kristoffer ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Acute myeloid leukemia; Leukemia related immunosuppression; Maintenance therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CALICHEAMICIN; CD20 ANTIBODY; CD200 ANTIBODY; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; GEMTUZUMAB; HISTAMINE; INTERLEUKIN 15; INTERLEUKIN 2; IPH2101 ANTIBODY; IPILIMUMAB; MONOCLONAL ANTIBODY; OZOGAMICIN; RITUXIMAB; ROQUINIMEX; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADAPTIVE IMMUNITY; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CHRONIC LYMPHATIC LEUKEMIA; CONSOLIDATION CHEMOTHERAPY; DRUG EFFICACY; DRUG TARGETING; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; LEUKEMIA CELL; LEUKEMIA RELAPSE; LYMPHOMA; MAINTENANCE THERAPY; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION;

ACUTE MYELOID LEUKEMIA; LEUKEMIA-RELATED IMMUNOSUPPRESSION; MAINTENANCE THERAPY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CYTOKINES; HUMANS; IMMUNOTHERAPY; LEUKEMIA, MYELOID, ACUTE; MAINTENANCE CHEMOTHERAPY; RECURRENCE;

EID: 84883554292     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2013.06.006     Document Type: Article

References (138)

1. Tallman M.S., Gilliland D.G., Rowe J.M. Drug therapy for acute myeloid leukemia. Blood 2005, 106:1154-1163.
2. Astrom M., Bodin L., Tidefelt U. Adjustment of incidence rates after an estimate of completeness and accuracy in registration of acute leukemias in a Swedish population. Leuk Lymphoma 2001, 41:559-570.
3. Schiller G., Gajewski J., Territo M., Nimer S., Lee M., Belin T., et al. Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia. Blood 1992, 80:2977-2982.
4. Kolb H.J. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 2008, 112:4371-4383.
5. Breems D.A., Van Putten W.L., Huijgens P.C., Ossenkoppele G.J., Verhoef G.E., Verdonck L.F., et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol 2005, 23:1969-1978.
6. Estey E.H. Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012, 87:89-99.
7. Martelli M.P., Sportoletti P., Tiacci E., Martelli M.F., Falini B. Mutational landscape of AML with normal cytogenetics: biological and clinical implications. Blood Rev 2013, 27:13-22.
8. Smith M.L., Hills R.K., Grimwade D. Independent prognostic variables in acute myeloid leukaemia. Blood Rev 2011, 25:39-51.
9. Byrd J.C., Mrozek K., Dodge R.K., Carroll A.J., Edwards C.G., Arthur D.C., et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002, 100:4325-4336.
10. Forman S.J., Rowe J.M. The myth of the second remission of acute leukemia in the adult. Blood 2013, 121:1077-1082.
11. Rowe J., LI X., Cassileth P.A. Very poor survival of patients with AML who relapse after achieving a first complete remission: the Eastern Cooperative Oncology Group Experience. ASH Annual Meeting Abstracts 2005, 106:546.
12. Pulte D., Gondos A., Brenner H. Improvements in survival of adults diagnosed with acute myeloblastic leukemia in the early 21st century. Haematologica 2008, 93:594-600.
13. Gyurkocza B., Storb R., Storer B.E., Chauncey T.R., Lange T., Shizuru J.A., et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. J Clin Oncol 2010, 28:2859-2867.
14. Mohty M., de Lavallade H., Ladaique P., Faucher C., Vey N., Coso D., et al. The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison. Leukemia 2005, 19:916-920.
15. Buchner T., Hiddemann W., Wormann B., Loffler H., Gassmann W., Haferlach T., et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood 1999, 93:4116-4124.
16. Buchner T., Urbanitz D., Hiddemann W., Ruhl H., Ludwig W.D., Fischer J., et al. Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. J Clin Oncol 1985, 3:1583-1589.
17. Greiner J., Ringhoffer M., Taniguchi M., Schmitt A., Kirchner D., Krahn G., et al. Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia. Exp Hematol 2002, 30:1029-1035.
18. Greiner J., Ringhoffer M., Taniguchi M., Hauser T., Schmitt A., Dohner H., et al. Characterization of several leukemia-associated antigens inducing humoral immune responses in acute and chronic myeloid leukemia. Int J Cancer 2003, 106:224-231.
19. Elisseeva O.A., Oka Y., Tsuboi A., Ogata K., Wu F., Kim E.H., et al. Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies. Blood 2002, 99:3272-3279.
20. Anguille S., Van Tendeloo V.F., Berneman Z.N. Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia. Leukemia 2012, 26:2186-2196.
21. Brune M., Hellstrand K. Remission maintenance therapy with histamine and interleukin-2 in acute myelogenous leukaemia. Br J Haematol 1996, 92:620-626.
22. Smits E.L., Berneman Z.N., Van Tendeloo V.F. Immunotherapy of acute myeloid leukemia: current approaches. Oncologist 2009, 14:240-252.
23. Lowdell M.W., Koh M.B. Immunotherapy of AML: future directions. J Clin Pathol 2000, 53:49-54.
24. Appelbaum F.R. Haematopoietic cell transplantation as immunotherapy. Nature 2001, 411:385-389.
25. Damiani D., Tiribelli M., Geromin A., Cerno M., Sperotto A., Toffoletti E., et al. Donor compatibility and performance status affect outcome of allogeneic haematopoietic stem cell transplant in patients with relapsed or refractory acute myeloid leukaemia. Ann Hematol 2012, 91:1937-1943.
26. Horowitz M.M., Gale R.P., Sondel P.M., Goldman J.M., Kersey J., Kolb H.J., et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990, 75:555-562.
27. Montagna D., Maccario R., Locatelli F., Montini E., Pagani S., Bonetti F., et al. Emergence of antitumor cytolytic T cells is associated with maintenance of hematologic remission in children with acute myeloid leukemia. Blood 2006, 108:3843-3850.
28. Greiner J., Schmitt M., Li L., Giannopoulos K., Bosch K., Schmitt A., et al. Expression of tumor-associated antigens in acute myeloid leukemia: implications for specific immunotherapeutic approaches. Blood 2006, 108:4109-4117.
29. van Luijn M.M., van den Ancker W., Chamuleau M.E., Ossenkoppele G.J., van Ham S.M., van de Loosdrecht A.A. Impaired antigen presentation in neoplasia: basic mechanisms and implications for acute myeloid leukemia. Immunotherapy 2010, 2:85-97.
30. Le Dieu R., Taussig D.C., Ramsay A.G., Mitter R., Miraki-Moud F., Fatah R., et al. Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts. Blood 2009, 114:3909-3916.
31. Chamuleau M.E., van de Loosdrecht A.A., Hess C.J., Janssen J.J., Zevenbergen A., Delwel R., et al. High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome. Haematologica 2008, 93:1894-1898.
32. Lion E., Willemen Y., Berneman Z.N., Van Tendeloo V.F., Smits E.L. Natural killer cell immune escape in acute myeloid leukemia. Leukemia 2012, 26:2019-2026.
33. Costello R.T., Sivori S., Marcenaro E., Lafage-Pochitaloff M., Mozziconacci M.J., Reviron D., et al. Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood 2002, 99:3661-3667.
34. Fauriat C., Just-Landi S., Mallet F., Arnoulet C., Sainty D., Olive D., et al. Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. Blood 2007, 109:323-330.
35. Orleans-Lindsay J.K., Barber L.D., Prentice H.G., Lowdell M.W. Acute myeloid leukaemia cells secrete a soluble factor that inhibits T and NK cell proliferation but not cytolytic function-implications for the adoptive immunotherapy of leukaemia. Clin Exp Immunol 2001, 126:403-411.
36. Sanchez-Correa B., Morgado S., Gayoso I., Bergua J.M., Casado J.G., Arcos M.J., et al. Human NK cells in acute myeloid leukaemia patients: analysis of NK cell-activating receptors and their ligands. Cancer Immunol Immunother 2011, 60:1195-1205.
37. Tajima F., Kawatani T., Endo A., Kawasaki H. Natural killer cell activity and cytokine production as prognostic factors in adult acute leukemia. Leukemia 1996, 10:478-482.
38. Costello R.T., Fauriat C., Sivori S., Marcenaro E., Olive D. NK cells: innate immunity against hematological malignancies?. Trends Immunol 2004, 25:328-333.
39. Aurelius J., Thoren F.B., Akhiani A., Brune M., Palmqvist L., Hansson M., et al. Monocytic AML cells inactivate anti-leukemic lymphocytes: role of NADPH oxidase/gp91phox expression and the PARP-1/PAR pathway of apoptosis. Blood 2012, 119:5832-5837.
40. Buggins A.G., Milojkovic D., Arno M.J., Lea N.C., Mufti G.J., Thomas N.S., et al. Microenvironment produced by acute myeloid leukemia cells prevents T cell activation and proliferation by inhibition of NF-kappaB, c-Myc, and pRb pathways. J Immunol 2001, 167:6021-6030.
41. Groh V., Wu J., Yee C., Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002, 419:734-738.
42. Vesely M.D., Kershaw M.H., Schreiber R.D., Smyth M.J. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011, 29:235-271.
43. Berthon C., Driss V., Liu J., Kuranda K., Leleu X., Jouy N., et al. In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors. Cancer Immunol Immunother 2010, 59:1839-1849.
44. Barclay A.N., Wright G.J., Brooke G., Brown M.H. CD200 and membrane protein interactions in the control of myeloid cells. Trends Immunol 2002, 23:285-290.
45. Coles S.J., Wang E.C., Man S., Hills R.K., Burnett A.K., Tonks A., et al. CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia. Leukemia 2011, 25:792-799.
46. Lanier L.L. NK cell recognition. Annu Rev Immunol 2005, 23:225-274.
47. Long E.O., Sik Kim H., Liu D., Peterson M.E., Rajagopalan S. Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu Rev Immunol 2013, 31:227-258.
48. Babor F., Fischer J.C., Uhrberg M. The role of KIR genes and ligands in leukemia surveillance. Front Immunol 2013, 4:27.
49. Ruggeri L., Capanni M., Urbani E., Perruccio K., Shlomchik W.D., Tosti A., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295:2097-2100.
50. Giebel S., Locatelli F., Lamparelli T., Velardi A., Davies S., Frumento G., et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 2003, 102:814-819.
51. Miller J.S., Cooley S., Parham P., Farag S.S., Verneris M.R., McQueen K.L., et al. Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood 2007, 109:5058-5061.
52. Hsu K.C., Gooley T., Malkki M., Pinto-Agnello C., Dupont B., Bignon J.D., et al. KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy. Biol Blood Marrow Transplant 2006, 12:828-836.
53. Davies S.M., Ruggieri L., DeFor T., Wagner J.E., Weisdorf D.J., Miller J.S., et al. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood 2002, 100:3825-3827.
54. Verheyden S., Demanet C. NK cell receptors and their ligands in leukemia. Leukemia 2008, 22:249-257.
55. Venstrom J.M., Pittari G., Gooley T.A., Chewning J.H., Spellman S., Haagenson M., et al. HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. N Engl J Med 2012, 367:805-816.
56. Sivori S., Carlomagno S., Falco M., Romeo E., Moretta L., Moretta A. Natural killer cells expressing the KIR2DS1-activating receptor efficiently kill T-cell blasts and dendritic cells: implications in haploidentical HSCT. Blood 2011, 117:4284-4292.
57. Biassoni R., Cantoni C., Pende D., Sivori S., Parolini S., Vitale M., et al. Human natural killer cell receptors and co-receptors. Immunol Rev 2001, 181:203-214.
58. Stewart C.A., Laugier-Anfossi F., Vely F., Saulquin X., Riedmuller J., Tisserant A., et al. Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors. Proc Natl Acad Sci U S A 2005, 102:13224-13229.
59. Bauer K., Rancea M., Roloff V., Elter T., Hallek M., Engert A., et al. Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia. Cochrane Database Syst Rev 2012, 11:CD008079.
60. Cang S., Mukhi N., Wang K., Liu D. Novel CD20 monoclonal antibodies for lymphoma therapy. J Hematol Oncol 2012, 5:64.
61. Kantarjian H., Thomas D., Wayne A.S., O'Brien S. Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia. J Clin Oncol 2012, 30:3876-3883.
62. Cheson B.D. Monoclonal antibody therapy of chronic lymphocytic leukaemia. Best Pract Res Clin Haematol 2010, 23:133-143.
63. Feldman E.J., Brandwein J., Stone R., Kalaycio M., Moore J., O'Connor J., et al. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Oncol 2005, 23:4110-4116.
64. Walter R.B., Appelbaum F.R., Estey E.H., Bernstein I.D. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood 2012, 119:6198-6208.
65. Bross P.F., Beitz J., Chen G., Chen X.H., Duffy E., Kieffer L., et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 2001, 7:1490-1496.
66. McKoy J.M., Angelotta C., Bennett C.L., Tallman M.S., Wadleigh M., Evens A.M., et al. Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. Leuk Res 2007, 31:599-604.
67. Kopecky K.J., Stuart R.K., Larson R.A., Nevill T.J., Stenke S., Slovak M.L., et al. Preliminary Results of Southwest Oncology Group Study S0106: An International Intergroup Phase 3 Randomized Trial Comparing the Addition of Gemtuzumab Ozogamicin to Standard Induction Therapy Versus Standard Induction Therapy Followed by a Second Randomization to Post-Consolidation Gemtuzumab Ozogamicin Versus No Additional Therapy for Previously Untreated Acute Myeloid Leukemia. Blood 2009, 114. [Abstract 790].
68. Castaigne S., Pautas C., Terre C., Raffoux E., Bordessoule D., Bastie J.N., et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 2012, 379:1508-1516.
69. Estey E.H., Giles F.J., Beran M., O'Brien S., Pierce S.A., Faderl S.H., et al. Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood 2002, 99:4222-4224.
70. Lo-Coco F., Cimino G., Breccia M., Noguera N.I., Diverio D., Finolezzi E., et al. Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood 2004, 104:1995-1999.
71. Eppert K., Takenaka K., Lechman E.R., Waldron L., Nilsson B., van Galen P., et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med 2011, 17:1086-1093.
72. Majeti R. Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells. Oncogene 2011, 30:1009-1019.
73. Jin L., Hope K.J., Zhai Q., Smadja-Joffe F., Dick J.E. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 2006, 12:1167-1174.
74. Majeti R., Chao M.P., Alizadeh A.A., Pang W.W., Jaiswal S., Gibbs K.D., et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 2009, 138:286-299.
75. Jin L., Lee E.M., Ramshaw H.S., Busfield S.J., Peoppl A.G., Wilkinson L., et al. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell 2009, 5:31-42.
76. Zhang L., Gajewski T.F., Kline J. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood 2009, 114:1545-1552.
77. Brahmer J.R., Tykodi S.S., Chow L.Q., Hwu W.J., Topalian S.L., Hwu P., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012, 366:2455-2465.
78. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366:2443-2454.
79. Wing K., Onishi Y., Prieto-Martin P., Yamaguchi T., Miyara M., Fehervari Z., et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008, 322:271-275.
80. Qureshi O.S., Zheng Y., Nakamura K., Attridge K., Manzotti C., Schmidt E.M., et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 2011, 332:600-603.
81. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
82. Lipson E.J., Drake C.G. Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res 2011, 17:6958-6962.
83. Szczepanski M.J., Szajnik M., Czystowska M., Mandapathil M., Strauss L., Welsh A., et al. Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia. Clin Cancer Res 2009, 15:3325-3332.
84. Shenghui Z., Yixiang H., Jianbo W., Kang Y., Laixi B., Yan Z., et al. Elevated frequencies of CD4(+) CD25(+) CD127lo regulatory T cells is associated to poor prognosis in patients with acute myeloid leukemia. Int J Cancer 2011, 129:1373-1381.
85. Vey N., Bourhis J.H., Boissel N., Bordessoule D., Prebet T., Charbonnier A., et al. A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. Blood 2012, 120:4317-4323.
86. Zhang Y., Patel S., Abdelouahab H., Wittner M., Willekens C., Shen S., et al. CXCR4 inhibitors selectively eliminate CXCR4-expressing human acute myeloid leukemia cells in NOG mouse model. Cell Death Dis 2012, 3:e396.
87. Peled A., Tavor S. Role of CXCR4 in the pathogenesis of acute myeloid leukemia. Theranostics 2013, 3:34-39.
88. Uy G.L., Rettig M.P., Motabi I.H., McFarland K., Trinkaus K.M., Hladnik L.M., et al. A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood 2012, 119:3917-3924.
89. Beider K., Begin M., Abraham M., Wald H., Weiss I.D., Wald O., et al. CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth. Exp Hematol 2011, 39:282-292.
90. Kuhne M.R., Mulvey T., Belanger B., Chen S., Pan C., Chong C., et al. BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies. Clin Cancer Res 2013, 19:357-366.
91. Tonks A., Hills R., White P., Rosie B., Mills K.I., Burnett A.K., et al. CD200 as a prognostic factor in acute myeloid leukaemia. Leukemia 2007, 21:566-568.
92. Kretz-Rommel A., Qin F., Dakappagari N., Cofiell R., Faas S.J., Bowdish K.S. Blockade of CD200 in the presence or absence of antibody effector function: implications for anti-CD200 therapy. J Immunol 2008, 180:699-705.
93. Wei G., Ni W., Chiao J.W., Cai Z., Huang H., Liu D. A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome. J Hematol Oncol 2011, 4:46.
94. Foon K.A., Smalley R.V., Riggs C.W., Gale R.P. The role of immunotherapy in acute myelogenous leukemia. Arch Intern Med 1983, 143:1726-1731.
95. Anguille S., Lion E., Willemen Y., Van Tendeloo V.F., Berneman Z.N., Smits E.L. Interferon-alpha in acute myeloid leukemia: an old drug revisited. Leukemia 2011, 25:739-748.
96. Goldstone A.H., Burnett A.K., Wheatley K., Smith A.G., Hutchinson R.M., Clark R.E. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood 2001, 98:1302-1311.
97. Simonsson B., Totterman T., Hokland P., Lauria F., Carella A.M., Fernandez M.N., et al. Roquinimex (Linomide) vs placebo in AML after autologous bone marrow transplantation. Bone Marrow Transplant 2000, 25:1121-1127.
98. Foa R., Meloni G., Guarini A., Vignetti M., Marchis D., Tosti S., et al. Interleukin 2 (IL2) in the management of acute myeloid leukemia: clinical and biological findings. Leukemia 1992, 6(Suppl. 3):115S-116S.
99. Baer M.R., George S.L., Caligiuri M.A., Sanford B.L., Bothun S.M., Mrozek K., et al. Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. J Clin Oncol 2008, 26:4934-4939.
100. Blaise D., Attal M., Reiffers J., Michallet M., Bellanger C., Pico J.L., et al. Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia in first complete remission. Eur Cytokine Netw 2000, 11:91-98.
101. Kolitz J.E., Hars V., DeAngelo D.J., Allen S.L., Shea T.C., Vij R., et al. Phase III trial of immunotherapy with recombinant interleukin-2 (rIL-2) versus observation in patients<60years with acute myeloid leukemia (AML) in first remission (CR1): preliminary results from Cancer and Leukemia Group B (CALGB) 19808. ASH Annual Meeting Abstracts 2007, 110:157.
102. Lange B.J., Smith F.O., Feusner J., Barnard D.R., Dinndorf P., Feig S., et al. Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group. Blood 2008, 111:1044-1053.
103. Lotzova E., Savary C.A., Herberman R.B. Induction of NK cell activity against fresh human leukemia in culture with interleukin 2. J Immunol 1987, 138:2718-2727.
104. Pautas C., Merabet F., Thomas X., Raffoux E., Gardin C., Corm S., et al. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70years: results of the ALFA-9801 study. J Clin Oncol 2010, 28:808-814.
105. Berry S.M., Broglio K.R., Berry D.A. Addressing the incremental benefit of histamine dihydrochloride when added to interleukin-2 in treating acute myeloid leukemia: a Bayesian meta-analysis. Cancer Invest 2011, 29:293-299.
106. Buyse M., Squifflet P., Lucchesi K.J., Brune M.L., Castaigne S., Rowe J.M. Assessment of the consistency and robustness of results from a multicenter trial of remission maintenance therapy for acute myeloid leukemia. Trials 2011, 12:86.
107. Hansson M., Asea A., Ersson U., Hermodsson S., Hellstrand K. Induction of apoptosis in NK cells by monocyte-derived reactive oxygen metabolites. J Immunol 1996, 156:42-47.
108. Thoren F.B., Romero A.I., Hellstrand K. Oxygen radicals induce poly(ADP-ribose) polymerase-dependent cell death in cytotoxic lymphocytes. J Immunol 2006, 176:7301-7307.
109. Kono K., Salazar-Onfray F., Petersson M., Hansson J., Masucci G., Wasserman K., et al. Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell-and natural killer cell-mediated cytotoxicity. Eur J Immunol 1996, 26:1308-1313.
110. Hellstrand K., Hermodsson S. Cell-to-cell mediated inhibition of natural killer cell proliferation by monocytes and its regulation by histamine H2-receptors. Scand J Immunol 1991, 34:741-752.
111. Mellqvist U.H., Hansson M., Brune M., Dahlgren C., Hermodsson S., Hellstrand K. Natural killer cell dysfunction and apoptosis induced by chronic myelogenous leukemia cells: role of reactive oxygen species and regulation by histamine. Blood 2000, 96:1961-1968.
112. Romero A.I., Thoren F.B., Brune M., Hellstrand K. NKp46 and NKG2D receptor expression in NK cells with CD56dim and CD56bright phenotype: regulation by histamine and reactive oxygen species. Br J Haematol 2006, 132:91-98.
113. Martner A., Thoren F.B., Aurelius J., Soderholm J., Brune M., Hellstrand K. Immunotherapy with histamine dihydrochloride for the prevention of relapse in acute myeloid leukemia. Expert Rev Hematol 2010, 3:381-391.
114. Romero A.I., Thoren F.B., Aurelius J., Askarieh G., Brune M., Hellstrand K. Post-consolidation immunotherapy with histamine dihydrochloride and interleukin-2 in AML. Scand J Immunol 2009, 70:194-205.
115. Brune M., Castaigne S., Catalano J., Gehlsen K., Ho A.D., Hofmann W.K., et al. Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial. Blood 2006, 108:88-96.
116. Thoren F.B., Romero A.I., Brune M., Hellstrand K. Histamine dihydrochloride and low-dose interleukin-2 as post-consolidation immunotherapy in acute myeloid leukemia. Expert Opin Biol Ther 2009, 9:1217-1223.
117. Aurelius J., Martner A., Brune M., Palmqvist L., Hansson M., Hellstrand K., et al. Remission maintenance in acute myeloid leukemia: impact of functional histamine H2 receptors expressed by leukemic cells. Haematologica 2012, 97:1904-1908.
118. Sakaguchi S. Regulatory T, cells: key controllers of immunologic self-tolerance. Cell 2000, 101:455-458.
119. Long S.A., Buckner J.H., Greenbaum C.J. IL-2 therapy in type 1 diabetes: "trials" and tribulations. Clin Immunol 2013, (epub ahead of print).
120. Liao W., Lin J.X., Leonard W.J. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 2013, 38:13-25.
121. Beyer M. Interleukin-2 treatment of tumor patients can expand regulatory T cells. Oncoimmunology 2012, 1:1181-1182.
122. Levin A.M., Bates D.L., Ring A.M., Krieg C., Lin J.T., Su L., et al. Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'. Nature 2012, 484:529-533.
123. Klein C., Inja W., Nicolini V., Claire D., Freimoser A., Herter S., et al. Novel tumor-targeted, engineered IL-2 variant (IL-2v)-based immunocytokines for immunotherapy of cancer. AACR Special Conference on Tumor Immunology 2012, (Abstract:55).
124. Waldmann T.A., Lugli E., Roederer M., Perera L.P., Smedley J.V., Macallister R.P., et al. Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. Blood 2011, 117:4787-4795.
125. Greiner J., Ono Y., Hofmann S., Schmitt A., Mehring E., Gotz M., et al. Mutated regions of nucleophosmin 1 elicit both CD4(+) and CD8(+) T-cell responses in patients with acute myeloid leukemia. Blood 2012, 120:1282-1289.
126. Maslak P.G., Dao T., Krug L.M., Chanel S., Korontsvit T., Zakhaleva V., et al. Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. Blood 2010, 116:171-179.
127. Van Tendeloo V.F., Van de Velde A., Van Driessche A., Cools N., Anguille S., Ladell K., et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci U S A 2010, 107:13824-13829.
128. Van Driessche A., Berneman Z.N., Van Tendeloo V.F. Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials. Oncologist 2012, 17:250-259.
129. Scheibenbogen C., Letsch A., Thiel E., Schmittel A., Mailaender V., Baerwolf S., et al. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood 2002, 100:2132-2137.
130. Brentjens R.J., Davila M.L., Riviere I., Park J., Wang X., Cowell L.G., et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013, 5:177ra38.
131. McKenna D.H., Kadidlo D.M., Cooley S., Miller J.S. Clinical production and therapeutic applications of alloreactive natural killer cells. Methods Mol Biol 2012, 882:491-507.
132. Di Giacomo A.M., Biagioli M., Maio M. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol 2010, 37:499-507.
133. Yan Y., Zhang G.X., Gran B., Fallarino F., Yu S., Li H., et al. IDO upregulates regulatory T cells via tryptophan catabolite and suppresses encephalitogenic T cell responses in experimental autoimmune encephalomyelitis. J Immunol 2010, 185:5953-5961.
134. Curti A., Pandolfi S., Valzasina B., Aluigi M., Isidori A., Ferri E., et al. Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells. Blood 2007, 109:2871-2877.
135. Buzyn A., Petit F., Ostankovitch M., Figueiredo S., Varet B., Guillet J.G., et al. Membrane-bound Fas (Apo-1/CD95) ligand on leukemic cells: a mechanism of tumor immune escape in leukemia patients. Blood 1999, 94:3135-3140.
136. Whiteside T.L. Immune modulation of T-cell and NK (natural killer) cell activities by TEXs (tumour-derived exosomes). Biochem Soc Trans 2013, 41:245-251.
137. Coles S.J., Hills R.K., Wang E.C., Burnett A.K., Man S., Darley R.L., et al. Expression of CD200 on AML blasts directly suppresses memory T-cell function. Leukemia 2012, 26:2148-2151.
138. Coles S.J., Hills R.K., Wang E.C., Burnett A.K., Man S., Darley R.L., et al. Increased CD200 expression in acute myeloid leukemia is linked with an increased frequency of FoxP3+ regulatory T cells. Leukemia 2012, 26:2146-2148.